Lieping Chen
Lieping Chen is an immunologist known for his works in T-lymphocyte biology and immunotherapy, especially in the development of anti-PD-1/PD-L1 cancer immunotherapy. Lieping Chen was born in Fuzhou, a southern China city near the East China Sea and had his medical training in Fujian Medical University in the same city. After the completion of a fellowship in immunology/oncology in Peking Union Medical College in Beijing, he moved to USA in 1986 to earn a PhD degree from Hahnemann Medical College (now Drexel University College of Medicine). After a short postdoctoral fellowship in University of Washington at Seattle, he spent 8 years in the Bristol-Myers Squibb Company’s Seattle branch, initially as a Research Scientist and promoted through the rank of Senior Scientist and Principal Scientist. He then joined Mayo Clinic as Associate Professor and promoted to Professor in 1999. In 2004, he moved to Johns Hopkins University School of Medicine as Professor of Oncology and Dermatology and Joined the faculty at Yale since 2011. He is a member of National Academy of Sciences, an Academician of Academia Sinica-Taiwan and Fellow, the AACR Academy, American Association for Cancer Research.